Gayle Marshall
Overview
Explore the profile of Gayle Marshall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eyers M, Irlam J, Marshall G, Smith V, Baker A, Frost L, et al.
Commun Biol
. 2024 Jun;
7(1):737.
PMID: 38890455
Muscle invasive bladder cancer (MIBC) is a molecularly diverse disease with varied clinical outcomes. Molecular studies typically employ bulk sequencing analysis, giving a transcriptomic snapshot of a section of the...
2.
Green V, Baldwin L, England J, Marshall G, Frost L, Moore C, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760543
Advancements in 3-Dimensional (3D) culture models for studying disease have increased significantly over the last two decades, but fully understanding how these models represent in vivo still requires further investigation....
3.
Eyres M, Bell J, Davies E, Fabre A, Alzetani A, Jogai S, et al.
Cell Rep
. 2022 Aug;
40(7):111230.
PMID: 35977489
A defining pathological feature of human lung fibrosis is localized tissue heterogeneity, which challenges the interpretation of transcriptomic studies that typically lose spatial information. Here we investigate spatial gene expression...
4.
Cani A, Dolce E, Darga E, Hu K, Liu C, Pierce J, et al.
Mol Oncol
. 2021 Dec;
16(10):1969-1985.
PMID: 34866317
Nearly all estrogen receptor (ER)-positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of...
5.
Paoletti C, Schiavon G, Dolce E, Darga E, Carr T, Geradts J, et al.
Clin Cancer Res
. 2018 Aug;
24(23):5860-5872.
PMID: 30082476
Purpose: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)-positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the...
6.
Veldman-Jones M, Brant R, Rooney C, Geh C, Emery H, Harbron C, et al.
Cancer Res
. 2015 Jun;
75(13):2587-93.
PMID: 26069246
Analysis of clinical trial specimens such as formalin-fixed paraffin-embedded (FFPE) tissue for molecular mechanisms of disease progression or drug response is often challenging and limited to a few markers at...
7.
Marshall G, Howard Z, Dry J, Fenton S, Heathcote D, Gray N, et al.
Biochem Soc Trans
. 2011 Mar;
39(2):456-9.
PMID: 21428919
AZD8055 is a small-molecule inhibitor of mTOR (mammalian target of rapamycin) kinase activity. The present review highlights molecular and phenotypic differences between AZD8055 and allosteric inhibitors of mTOR such as...
8.
Hickinson D, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, et al.
Clin Cancer Res
. 2010 Feb;
16(4):1159-69.
PMID: 20145185
Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and erbB3 receptor signaling, using the novel...
9.
Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies B, Wilkinson R, et al.
Anticancer Drugs
. 2009 Aug;
20(10):856-66.
PMID: 19657272
Two small-molecule epidermal growth factor receptor tyrosine kinase inhibitors, gefitinib and erlotinib, have been approved for the treatment of non-small-cell lung cancer. Here, we compare the pharmacology and pharmacokinetics of...